Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · March 01, 2018

Larotrectinib Effective in TRK Fusion–Positive Cancers in Adults and Children

The New England Journal of Medicine

 

Additional Info

The New England Journal of Medicine
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
N. Engl. J. Med 2018 Feb 22;378(8)731-739, A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, M Nathenson, RC Doebele, AF Farago, AS Pappo, B Turpin, A Dowlati, MS Brose, L Mascarenhas, N Federman, J Berlin, WS El-Deiry, C Baik, J Deeken, V Boni, R Nagasubramanian, M Taylor, ER Rudzinski, F Meric-Bernstam, DPS Sohal, PC Ma, LE Raez, JF Hechtman, R Benayed, M Ladanyi, BB Tuch, K Ebata, S Cruickshank, NC Ku, MC Cox, DS Hawkins, DS Hong, DM Hyman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading